• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biochip J . A New Quantum Dot-Based Lateral Flow Immunoassay for the Rapid Detection of Influenza Viruses

tetano

Editor, Senior Moderator
Biochip J


. 2022 Mar 21;1-8.
doi: 10.1007/s13206-022-00053-4. Online ahead of print.
A New Quantum Dot-Based Lateral Flow Immunoassay for the Rapid Detection of Influenza Viruses


Soo-Kyung Kim[SUP] 1 2 [/SUP], Heungsup Sung[SUP] 1 [/SUP], Sang-Hyun Hwang[SUP] 1 [/SUP], Mi-Na Kim[SUP] 1 [/SUP]



Affiliations
Free PMC article

Abstract

Rapid and accurate diagnosis of influenza is crucial to contain influenza virus outbreaks. In clinical settings, lateral flow immunoassays (LFIAs) are widely used for rapid influenza antigen detection. The choice of label plays an important role in determining the sensitivity of the LFIA. Quantum dots are one of the most promising fluorescent reporters. Here, we evaluated a novel quantum dot-based assay, QuantumPACK Easy Influenza A + B (QuantumPACK Easy; BioSquare Inc., Korea). A total of 394 nasopharyngeal swab samples, including 94 influenza A virus-positive, 98 influenza B virus-positive, 175 influenza A and B virus-negative, and 27 other respiratory pathogen-positive samples, were collected. Samples were tested with QuantumPACK Easy, Allplex RP real-time RT-PCR assay (Allplex RP; Seegene, Korea), and Sofia Influenza A + B FIA (Sofia; Quidel, CA, USA). The sensitivity and specificity of QuantumPACK Easy was analyzed using the Allplex RP assay. The agreement between QuantumPACK Easy and Sofia assays was also analyzed. The sensitivity of QuantumPACK Easy for influenza A and B was 80.9% and 83.7%, respectively. The specificity of QuantumPACK Easy was 100%. Cross-reactivity with other respiratory pathogens was not observed. Total agreement between QuantumPACK Easy and Sofia was 89.6% (kappa 0.783). The sensitivity of the Sofia assay was 66.0% for influenza A virus and 61.2% for influenza B virus. QuantumPACK Easy had acceptable performance, with better sensitivity than a commercially available antigen detection assay, possibly due to the characteristics of the quantum dot.

Keywords: Influenza; Lateral flow immunoassay; Quantum dot; Rapid antigen test.
 
Back
Top Bottom